Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Scholar Rock Holding CorporationNASDAQ: SRRK

Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026

Net change in cash turns negative

Q3 FY2026 net change in cash was -$70.82M, compared with $135.25M a year earlier. Trailing-twelve-month net change in cash was -$21.31M.

Context

  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$70.82M or moves back toward the trailing-twelve-month quarterly average of -$5.33M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$70.82M-24.9% QoQ
Last fiscal yearDec 2025
$147.05M+93.4% YoY
LTMSep 2026
-$21.31M-110.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-152.4%——
1 year+93.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
147.05M USD
Year-over-year change
+93.4%
4-year CAGR
+29.4%

Net Change in Cash vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's LTM Sep 2026 net change in cash of $21.31M is the smallest of the 11 companies compared; the peer median is $32M.
  • Its year-over-year change of -110.1% is the 6th highest of 11, against a peer median of -113.0%.
  • Net change in cash amounts to 3738.4% of revenue for SRRK, versus a peer median of 10.1%.
SRRK Competitors Peer median
Net Change in Cash for SRRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$221.13M +218.6%-35.6%10.1%
DYNDyne Therapeutics, Inc.LTM Jun 2026$191.46M +255.6%——
STOKStoke Therapeutics, Inc.LTM Mar 2026$116.23M -220.5%+11.8%362.3%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$95.61M -136.2%-57.8%478.0%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$70.84M -135.1%—9.9%
BEAMBeam Therapeutics Inc.LTM Jun 2026$62.27M +513.4%—39.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$42.04M -1225.2%—4.4%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$33.26M -90.9%+27.2%3.3%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$22.68M +1794.5%+44.7%—
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$21.95M -230.0%——
SRRKScholar Rock Holding CorporationLTM Sep 2026$21.31M -110.1%—3738.4%
Peer median (excluding SRRK) $32M-113.0%+11.8%10.1%

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Depreciation & Amortization2.63M2.99M2.84M1.94M1.66M
Deferred Income Tax00000
Stock-Based Compensation23.15M27.7M27.14M36.63M75.6M
Change in Working Capital(28.44M)(34.39M)(10.61M)6.59M(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.02M(251K)(529K)6.63M208K
Other Working Capital(29.46M)(34.14M)(10.09M)(36K)(1.26M)
Other Non-Cash Items7.67M5.51M1.19M186K1.7M
Operating Cash Flow(126.79M)(132.69M)(145.23M)(200.95M)(300.04M)
Capital Expenditures(5.25M)(1.06M)(71K)(98K)(602K)
Acquisitions (Net)00000
Purchases of Investments(60.44M)(300.63M)(290.8M)(293.16M)(98.01M)
Sales of Investments200M130M332M217.2M317.3M
Other Investing Activities0013K00
Investing Cash Flow134.32M(171.7M)41.14M(76.06M)218.69M
Debt Repayment24.98M(975K)0049.14M
Common Stock Issued13.1M195.32M97.71M324.41M179.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.87M492K4.87M28.61M0
Financing Cash Flow44.95M194.83M102.57M353.03M228.4M
Effect of Forex Changes0000(2K)
Net Change in Cash52.48M(109.56M)(1.51M)76.02M147.05M
Free Cash Flow(132.04M)(133.76M)(145.3M)(201.05M)(300.64M)

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.